Caveolin-1 ( CAV1 ) Is a Target of EWS/FLI-1 and a Key Determinant of the Oncogenic Phenotype and Tumorigenicity of Ewing's Sarcoma Cells
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Tumors of the Ewing's sarcoma family (ESFT), such as Ewing's sarcoma (EWS) and primitive neuroectodermal tumors (PNET), are highly aggressive malignancies predominantly affecting children and young adults. ESFT express chimeric transcription factors encoded by hybrid genes fusing the EWS gene with several ETS genes, most commonly FLI-1. EWS/FLI-1 proteins are responsible for the malignant phenotype of ESFT, but only few of their transcriptional targets are known. Using antisense and short hairpin RNA–mediated gene expression knockdown, array analyses, chromatin immunoprecipitation methods, and reexpression studies, we show that caveolin-1 (CAV1) is a new direct target of EWS/FLI-1 that is overexpressed in ESFT cell lines and tumor specimens and is necessary for ESFT tumorigenesis. CAV1 knockdown led to up-regulation of Snail and the concomitant loss of E-cadherin expression. Consistently, loss of CAV1 expression inhibited the anchorage-independent growth of EWS cells and markedly reduced the growth of EWS cell–derived tumors in nude mice xenografts, indicating that CAV1 promotes the malignant phenotype in EWS carcinogenesis. Reexpression of CAV1 or E-cadherin in CAV1 knockdown EWS cells rescued the oncogenic phenotype of the original EWS cells, showing that the CAV1/Snail/E-cadherin pathway plays a central role in the expression of the oncogenic transformation functions of EWS/FLI-1. Overall, these data identify CAV1 as a key determinant of the tumorigenicity of ESFT and imply that targeting CAV1 may allow the development of new molecular therapeutic strategies for ESFT patients. (Cancer Res 2006; 66(20): 9937-47)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Khan, J., Wei, J. S., Ringnér, M., Saal, L. H., Ladanyi, M., Westermann, F., Berthold, F., Schwab, M., Antonescu, C. R., Peterson, C., et al. (2001) · Nature Medicine · doi:10.1038/89044 · Cited by 2,644 · cited 2×
“Together with the high CAV1 expression detected in EWS cell lines and most EWS tumor samples tested, these data provide strong evidence supporting that CAV1 is a direct EWS/FLI-1 transcriptional target, are consistent with the reported association of CAV1 expression with metastasis and bad prognosis for different canc…”
Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours
Delattre, O., Zucman, J., Plougastel, B., Desmaze, C., Melot, T., Peter, M., Kovar, H., Joubert, I., de Jong, P., Rouleau, G., et al. (1992) · Nature · doi:10.1038/359162a0 · Cited by 1,907 · cited 1×
“These EWS/FLI-1 genes are heterogeneous with regard to the location of the translocation junction, resulting in different breakpoints (3).”
Self-citationEts target genes: past, present and future
Sementchenko, V. I., & Watson, D. K. (2000) · Oncogene · doi:10.1038/sj.onc.1204034 · Cited by 371 · cited 14×
“Considering the negative results obtained with PCR primers for a CAV1 gene region that would not cofractionate with the EBS-containing fragment, data from chromatin immunoprecipitation experiments strongly supported the EWS/FLI-1 binding to the CAV1 promoter EBS, which, interestingly, is a nonconsensus ETS site.”
InfluentialGene expression profiling of human sarcomas: insights into sarcoma biology.
Baird, K., Davis, S., Antonescu, C. R., Harper, U. L., Walker, R. L., Chen, Y., Glatfelter, A. A., Duray, P. H., & Meltzer, P. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1699 · Cited by 353 · cited 2×
“Together with the high CAV1 expression detected in EWS cell lines and most EWS tumor samples tested, these data provide strong evidence supporting that CAV1 is a direct EWS/FLI-1 transcriptional target, are consistent with the reported association of CAV1 expression with metastasis and bad prognosis for different canc…”
Cited by
Microsatellites as EWS/FLI response elements in Ewing's sarcoma
Gangwal, K., Sankar, S., Hollenhorst, P. C., Kinsey, M., Haroldsen, S. C., Shah, A. A., Boucher, K. M., Watkins, W. S., Jorde, L. B., Graves, B. J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801073105 · Cited by 297
Identification of Cancer Stem Cells in Ewing's Sarcoma
Suvà, M.-L., Riggi, N., Stehle, J.-C., Baumer, K., Tercier, S., Joseph, J.-M., Suvà, D., Clément, V., Provero, P., Cironi, L., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2242 · Cited by 302
Caveolin-1 in tumor progression: the good, the bad and the ugly
Goetz, J. G., Lajoie, P., Wiseman, S. M., & Nabi, I. R. (2008) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9160-9 · Cited by 299
Promiscuous partnerships in Ewing's sarcoma
Sankar, S., & Lessnick, S. L. (2011) · Cancer Genetics · doi:10.1016/j.cancergen.2011.07.008 · Cited by 258
Guillon, N., Tirode, F., Boeva, V., Zynovyev, A., Barillot, E., & Delattre, O. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004932 · Cited by 218
“These includes TGFbRII [15], cyclinD1 [16], Id2 and c-Myc [17], IGFBP3 [18], PTPL1 [19], cyclinE [20], MK-STYX [21], caveolin1 [22] and Dax1/NR0B1 [23,24].”
Metadata
- Authors
- Tirado, O. M., Mateo-Lozano, S., Villar, J., Dettin, L. E., Llort, A., Gallego, S., Ban, J., Kovar, H., & Notario, V.
- Venue
- Cancer Research
- Published
- 2006-10-15
- Volume
- 66
- Issue
- 20
- Pages
- 9937-9947
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2101854267
- Cited by
- 143
- References
- 4
- FWCI
- 3.74
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Caveolin-1 ( CAV1 ) Is a Target of EWS/FLI-1 and a Key Determinant of the Oncogenic Phenotype and Tumorigenicity of Ewing's Sarcoma Cells. https://app.cochat.ai/papers/10.1158/0008-5472.can-06-0927
- The paper
- Tirado, O. M., Mateo-Lozano, S., Villar, J., Dettin, L. E., Llort, A., Gallego, S., Ban, J., Kovar, H., & Notario, V. (2006). Caveolin-1 ( CAV1 ) Is a Target of EWS/FLI-1 and a Key Determinant of the Oncogenic Phenotype and Tumorigenicity of Ewing's Sarcoma Cells. Cancer Research. https://doi.org/10.1158/0008-5472.can-06-0927
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.